Best Practices For A 340B Hospital Looking To Build An Onsite Specialty Pharmacy

March 28, 2024340B, Outpatient Tracking, Retail / Outpatient Pharmacy, Specialty Drugs, Specialty Pharmacy

ProxsysRx recently gathered three of its corporate executives for an in-depth discussion of how an eligible health system can optimize revenues from its 340B program and its retail pharmacy, to help build and fund an onsite specialty pharmacy. Below is a lightly-edited transcript of that discussion. NOTE: If you’d prefer to watch the complete video … Read More

For TMH Pharmacist-In-Charge Mariana Elia, It’s All About The Relationship.

March 20, 2024Meds To Beds, Pharmacy Careers, ProxsysRx Profile, Retail / Outpatient Pharmacy

If you’re a first-time patient of ProxsysRx’s pharmacy at Tallahassee Memorial Healthcare, and you want to get Mariana Elia talking, really talking, it helps to know key trigger words. Key words and phrases like “Hello,” “How are you?” and “Tell me about yourself.” All highly effective for starting a lively conversation, to be sure. But … Read More

The Best 340B Program Is More Than Just A 340B Program. Much More.

March 12, 2024340B, Bedside Prescription Delivery, Contract Pharmacy, Drug Manufacturer Restrictions, Meds To Beds, Specialty Drugs, Specialty Pharmacy, TPA / TPAs

Congress established the 340B program in 1992 to help non-profit hospitals fill-in the significant revenue gaps inherent to their business models. What the bill’s supporters did not foresee, and what very few eligible health systems realize — even today — is that 340B can function as the central hub of a multi-point program. One that … Read More

Leveraging Partnerships With Drug Manufacturers To Overcome 340B Restrictions On Specialty Drugs

March 1, 2024340B, 340B ESP, Bedside Prescription Delivery, Drug Manufacturer Restrictions, Medicare, Meds To Beds, PBM, Specialty Drugs, Specialty Drugs, Specialty Pharmacy

It’s no secret that the 340B Drug Pricing Program has been a lifeline for eligible health systems, enabling them to fill-in the massive revenue gaps inherent to the non-profit-hospital business model (and, in the process, support their mission of providing quality care to our nation’s most vulnerable patients) through access to discounted prescription refills. At … Read More

Your Hospital’s 340B Contract Pharmacy Network Is Not What It Should Be.

February 15, 2024340B, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Patient Eligibility, PBM, Prescription Discounts, Specialty Drugs, Specialty Drugs, Specialty Pharmacy, Specialty Pharmacy, TPA / TPAs, Uncategorized

Based on our experience, it’s a claim we can make with 100% certainty. Since 2019, when ProxsysRx launched its 340B Support Services division, we’ve managed the 340B programs of 18 health systems. Altogether, we’ve generated more than $500 million in 340B Savings and Revenue for those health systems — $98M in the first 10 months … Read More

How ProxsysRx Quadrupled One 340B Entity’s Savings & Revenue In A Single Quarter

January 15, 2024340B, Contract Pharmacy, Covered Entities, Drug Manufacturer Restrictions, Retail / Outpatient Pharmacy, Specialty Pharmacy

In late 2022, ProxsysRx’s team initiated 340B Program-Management support for a 198-bed, full-service, community and regional non-profit medical center located in the Northeast. After weeks of laying all the necessary groundwork to manage its 340B program, we began actively submitting eligible prescriptions this past January. By the end of Q1, the hospital’s 2023 340B savings … Read More

ProxsysRx’s Meds To Beds Program Makes Immediate Impact Upon Launch At TMH

November 8, 2023340B, Bedside Prescription Delivery, Meds To Beds, Prescription Discounts, Retail / Outpatient Pharmacy, Specialty Pharmacy

To date, we’ve published a dozen posts either detailing, or mentioning-in-passing, the clinical and financial benefits a well-run Meds To Beds program offers hospitals and the patients they serve. Which is why we thought it was time to report some of the personal benefits our program delivers — with a handful of stories we’ve heard … Read More

Drug Manufacturers’ 340B Restrictions Generate New Round Of Media Scrutiny & Criticism

November 1, 2023340B, 340B ESP, Drug Manufacturer Restrictions, News Updates

In the past week, no less than three articles have called attention to the restrictions drug manufacturers have imposed to evade their legal responsibility to honor 340B program prescription discounts — as well as the impact those restrictions have had on 340B-eligible nonprofit entities’ ability to serve their patients and communities. “Don’t believe drug companies: … Read More